{
    "nct_id": "NCT03960840",
    "official_title": "Phase I/II, Open Label, Multicenter Study of Rapcabtagene Autoleucel in Adult Patients With CLL/SLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL",
    "inclusion_criteria": "* ECOG performance status 0-1 for ALL and DLBCL\n* ECOG performance status 0-2 for 1L HR LBCL at screening\n* CLL or SLL diagnosis according to iwCLL criteria\n* CLL/SLL in SD or PR after at least 6 months of ibrutinib, either as second or subsequent line of therapy\n* DLBCL diagnosis by local histopathology\n* DLBCL relapsed or refractory after 2 or more lines of therapy, including autologous hematopoietic stem cell transplantation (HSCT)\n* Refractory or relapsed CD19-positive ALL\n* ALL with morphologic disease in the bone marrow\n\n  1L HR LBCL - Considered to be high-risk based on at least 1 of the following at diagnosis:\n  * IPI score of 3, 4 or 5\n  * MYC and BCL2 and/or BCL6 rearrangement (DH/TH lymphoma)\n* Participants must have received 2 cycles of frontline therapy for LBCL with R-CHOP or Pola-R-CHP or DA-EPOCH-R. Participants with DH/TH lymphoma must have received at least one cycle (the most recent) DA-EPOCH-R.\n* Participants must have a positive PET per Lugano classification (Deauville PET score of 4 or 5 and an overall response of PR/SD) after 2 cycles of frontline CIT. Note: Patient's with Deauville PET score of 5 and overall response of PD, or with Deauville PET score of 1, 2, or 3 and overall response of CR, are not eligible for this trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Prior CD19-directed therapy\n* Prior administration of a genetically engineered cellular product\n* Prior allogeneic HSCT\n* Richter's transformation\n\n  * For 1L HR LBCL: Richter's transformation, Burkitt lymphoma, primary DLBCL of CNS, DLBCL associated with chronic inflammation, intravascular large B-cell lymphoma, ALK- positive large B-cell lymphoma, HHV8 positive LBCL, DLBCL leg type or EBV positive DLBCL, NOS.\n* Active CNS lymphoma\n\n  * For 1L HR LBCL: Active or prior history CNS involvement by malignancy\n* Targeted small molecule or kinase inhibitor within 2 weeks from leukapheresis\n\nOther protocol-defined inclusion/exclusion may apply.",
    "miscellaneous_criteria": ""
}